Ross JS - Search Results

1

The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy.

Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L, Bloom KJ. Ross JS, et al. Oncologist. 2003;8(4):307-25. doi: 10.1634/theoncologist.8-4-307. Oncologist. 2003. PMID: 12897328 Free article. Review.

2

Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma.

Ross JS, Sheehan CE, Hayner-Buchan AM, Ambros RA, Kallakury BV, Kaufman RP Jr, Fisher HA, Rifkin MD, Muraca PJ. Ross JS, et al. Cancer. 1997 Jun 1;79(11):2162-70. doi: 10.1002/(sici)1097-0142(19970601)79:11<2162::aid-cncr14>3.0.co;2-u. Cancer. 1997. PMID: 9179063

3

HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization.

Ross JS, Sheehan C, Hayner-Buchan AM, Ambros RA, Kallakury BV, Kaufman R, Fisher HA, Muraca PJ. Ross JS, et al. Hum Pathol. 1997 Jul;28(7):827-33. doi: 10.1016/s0046-8177(97)90157-x. Hum Pathol. 1997. PMID: 9224752

4

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.

Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, Hung G, Robinson RA, Harris C, El-Naggar A, Slamon DJ, Phillips RN, Ross JS, Wolman SR, Flom KJ. Press MF, et al. Among authors: ross js. J Clin Oncol. 1997 Aug;15(8):2894-904. doi: 10.1200/JCO.1997.15.8.2894. J Clin Oncol. 1997. PMID: 9256133

5

Identification of HER-2/neu oncogene amplification by fluorescence in situ hybridization in stage I endometrial carcinoma.

Riben MW, Malfetano JH, Nazeer T, Muraca PJ, Ambros RA, Ross JS. Riben MW, et al. Among authors: ross js. Mod Pathol. 1997 Aug;10(8):823-31. Mod Pathol. 1997. PMID: 9267826

6

Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44s downregulation, and HER-2/neu oncogene amplification with recurrence in prostatic adenocarcinomas.

Kallakury BV, Sheehan CE, Ambros RA, Fisher HA, Kaufman RP Jr, Muraca PJ, Ross JS. Kallakury BV, et al. Among authors: ross js. J Clin Oncol. 1998 Apr;16(4):1302-9. doi: 10.1200/JCO.1998.16.4.1302. J Clin Oncol. 1998. PMID: 9552030

7

Prognostic factors in gastric cancer.

Brien TP, Depowski PL, Sheehan CE, Ross JS, McKenna BJ. Brien TP, et al. Among authors: ross js. Mod Pathol. 1998 Sep;11(9):870-7. Mod Pathol. 1998. PMID: 9758367

8

The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.

Ross JS, Fletcher JA. Ross JS, et al. Stem Cells. 1998;16(6):413-28. doi: 10.1002/stem.160413. Stem Cells. 1998. PMID: 9831867 Review.

9

HER-2/neu oncogene amplification by fluorescence in situ hybridization in epithelial tumors of the ovary.

Ross JS, Yang F, Kallakury BV, Sheehan CE, Ambros RA, Muraca PJ. Ross JS, et al. Am J Clin Pathol. 1999 Mar;111(3):311-6. doi: 10.1093/ajcp/111.3.311. Am J Clin Pathol. 1999. PMID: 10078105 Review.

10

The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy.

Ross JS, Fletcher JA. Ross JS, et al. Semin Cancer Biol. 1999 Apr;9(2):125-38. doi: 10.1006/scbi.1998.0083. Semin Cancer Biol. 1999. PMID: 10202134 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,701 results

Search Page

Filters